Comparing SG&A Expenses: Geron Corporation vs Taro Pharmaceutical Industries Ltd. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Geron Corporation and Taro Pharmaceutical Industries Ltd. over the past decade.

Geron Corporation's Steady Climb

From 2014 to 2023, Geron Corporation's SG&A expenses have shown a significant upward trend, increasing by over 300%. This rise reflects the company's strategic investments in administrative capabilities and market expansion.

Taro Pharmaceutical's Consistent Leadership

Taro Pharmaceutical Industries Ltd. has consistently maintained higher SG&A expenses compared to Geron, with a notable 115% increase from 2014 to 2023. This suggests a robust operational framework and a strong market presence.

Insights and Implications

While both companies have shown growth, Taro's expenses are consistently higher, indicating a larger scale of operations. Missing data for 2024 suggests ongoing developments worth monitoring.